1. HOME
  2. 시작페이지로 설정

페이스북 트위터에 공유 RSS
 

영남매일신문


International news ▶

  • 정치
  • 경제
  • 사회/문화
  • 국제
  • 연예/스포츠
  • 라이프
  • 오피니언
  • 지역뉴스
  • 지역인사
  • 2026.11.16 기상청GO

    영남매일신문

    [연합뉴스수신] NUS Scientists use Patient Derived Cancer Cell Culture

    국제 | 12-01 09:24

    NUS Scientists use Patient Derived Cancer Cell Culture
    to Predict Survival and Treatment Outcome

    [편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.

    (SINGAPORE, Dec. 1, 2015 PRNewswire=연합뉴스) Scientists from the National University of Singapore (NUS) have developed a novel technique to efficiently culture clusters containing circulating tumour cells (CTCs) in 14 days. Using the technique, the team achieved a success rate of more than 60 per cent in culturing CTCs from patients with metastatic breast cancer, the highest known success record to-date. This breakthrough brings researchers a step closer towards enabling personalised cancer treatment and monitoring.

    A paper describing the collaborative work conducted by scientists from the Mechanobiology Institute, Singapore (MBI) and Cancer Science Institute of Singapore (CSI) at NUS, together with the National University Cancer Institute, Singapore (NCIS), was published in the medical journal Oncotarget (2015).

    CTCs are 'runaway' cancer cells that escape from primary or secondary tumours. They circulate in the bloodstream and eventually invade into other parts of the body where they establish metastasis. CTCs can be found even at early stages of cancer.

    However, CTCs comprise many sub-populations and occur at extremely low frequencies in blood. Thus, its population needs to be expanded before they can be used for clinical analysis.

    Professor Lim Chwee Teck from MBI, one of the study's lead authors, explained, "Being able to capture CTCs and grow them efficiently from a blood sample is a big step forward in liquid biopsy for tumour diagnosis and cancer treatment monitoring. This could potentially mean that biopsy for cancer diagnosis and prognosis could be done using a blood test, which is minimally invasive, instead of having to retrieve cells from the tumour itself. Results of the tests on these CTCs could help doctors assess the best therapy options for a patient, and frequent blood tests can also be done during the course of an anti-cancer treatment to provide a real-time monitoring of a patient's progress during treatment."

    Dr Lee Soo Chin from NCIS and CSI, the study's clinical lead added, "Tests can potentially be done on the cultured CTCs to guide the selection of drug therapy. Cultured CTCs of individual patients can be tested for drug sensitivity to determine the responsiveness of the CTCs to the drugs used in the cancer treatment. This could allow doctors to decide on the most suitable drug for the patient based on the drug sensitivity results. As the CTCs can be cultured in a short time period, the entire testing process can take as short as four weeks -- two weeks for culturing the CTCs and two weeks for drug screening."

    Current methods of culturing CTCs are either inefficient or required the elimination of non-cancerous cells that led to the damage or loss of some CTCs in the process.

    Using a combination of specially designed microwells and oxygen-deficient growth conditions, NUS scientists have successfully created an ideal environment for tumour cells to grow while other non-cancerous cells gradually undergo cell death.

    This novel technique was tested on 226 clinical blood samples obtained from 92 metastatic breast cancer patients on anti-cancer therapy. The team recorded a success rate of over 60 per cent in culturing clusters containing CTCs -- more than two to three times higher than conventional methods.

    The team is also currently developing new technologies for liquid biopsies that will allow single cell analysis to obtain critical information that will be useful to scientists and clinicians to better treat cancer.

    Prof Lim hopes to embark on the development of novel technologies that can contribute towards personalised or precision medicine.

    More information about the study: http://news.nus.edu.sg/press-releases/9723-cancer-bloodtest-monitor-treatment-outcome

    MEDIA CONTACT:
    Amal Naquiah
    National University of Singapore
    DID: (65) 6516-5125
    Email: amal@nus.edu.sg

    Logo - http://photos.prnasia.com/prnh/20151130/8521508170LOGO

    SOURCE: National University of Singapore
    (끝)


    <저작권자(c) 연합뉴스, 무단 전재-재배포 금지>
    주요뉴스 뉴스속보
    연예 지역뉴스 지역인사

    가수 겸 배우 탑(최승현·39)과 나나(35)가 5개월째 열애 중이다.탑의 소속...

      배우 구교환(44)과 이옥섭 감독(39)이 이미 부부라는 사실이 뒤늦게 ...

     모델 출신 배우 변우석이 서울 한남동 고급 아파트 한남더힐을 130억 ...

     개그맨 이혁재 씨가 음주운전을 하다가 오토바이를 들이받는 사고를 내...

     가수 겸 배우 김민종이 자신의 불법도박 의혹을 제기한 MC몽(신동현)을...

     경기 양평 남양평IC 인근서 새벽 사고…승합차 탑승자 현장서 숨진 채 ...

                        &n...

     지역 내 응급안전안심서비스 수행기관 17곳에 전용차량 보급전국 최초 ...

    부산시는 센텀종합병원과 좋은삼선병원을 지역외상거점병원으로 최종 선정했...

      BNK 부산은행 제공  ​지역 금융그룹의 투자 전...

    김용남 전 의원, 시사인 유튜브 방송서 주장원본보기통일교(세계평화통일가정...

     미국 시민권 포기, 39개월간 복무원본보기이재용 삼성전자 회장 장남 ...

                 윤동한 .  콜마홀딩...

    박근혜 국정농단 계기로 제일모직-삼성물산 합병 수사 촉발…기소 4년10개월...

    https://imgnews.pstatic.net/image/023/2025/07/10/0003916143_001_20250710...

    서비스안내

  • 정치
    청와대/국회
    정부/지자체
    정당
    선거
    국방
    북한
    기타
  • 경제
    기업/산업
    부동산
    자동차
    IT/과학
    유통/소비자
    증권/금융
    글로벌경제
  • 사회/문화
    사건/사고
    정책
    지역
    사회
    교육
    문화
  • 연예/스포츠
    연예가화제
    TV/방송
    영화
    음악
    미술
    스포츠종합
    전시/공연
  • 라이프
    재테크
    패션/뷰티
    여행
    푸드
    건강
    날씨
  • 오피니언
    사설
    컬럼
    만평
    독자마당
  • 국제
    미국/북미
    중국
    러시아
    일본
    유럽
    중동
    중남미
    동남아시아
    기타
  • 지역뉴스
    전국
    부산
    울산
    창원
    진주
    통영권
    함안권
    기타
  • 지역인사
    인물
    기업
    단체
    기타
  • 제휴·광고문의
  • |
  • 기사제보
  • |
  • 기자소개
  • |
  • 고객센터
  • |
  • 저작권정책
  • |
  • 개인정보취급방침
  • |
  • 이메일무단수집거부
  • |
  • 고충처리인 활동사례
  • 상호: 영남매일신문(주) | 사업자등록번호: 506-81-85807 | 대표: 강호성 | 신문등록번호 : 부산 가00021 / 인터넷신문등록번호 : 부산, 아00272

    전화: 051-867-3909 | 팩스: 051-861-3463 | 주소: 부산광역시 연제구 중앙대로 1111, 1701호 (연산동, 위드타워)

    copyright ⓒ 2015 newsyn.co.kr All right reserved. | web@newsyn.co.kr